Disclaimer:

Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.

Cyclobenzaprine Hydrochloride

&times

Overview

What is Cyclobenzaprine Hydrochloride?

Cyclobenzaprine hydrochloride is a white, crystalline tricyclic amine salt. It has a melting point of 217°C, and a pK of 8.47 at 25°C. It is freely soluble in water and alcohol, sparingly soluble in isopropanol, and insoluble in hydrocarbon solvents. If aqueous solutions are made alkaline, the free base separates. Cyclobenzaprine HCl is designated chemically as 3-(5-dibenzo[]cyclohepten-5-ylidene)--dimethyl-1-propanamine, hydrochloride, and has the following structural formula:

Cyclobenzaprine hydrochloride tablets, USP are available for oral administration as 5 mg, 7.5 mg and 10 mg tablets. Cyclobenzaprine hydrochloride 5 mg, 7.5 mg and 10 mg tablets contain the following inactive ingredients: colloidal silicon dioxide, croscarmellose sodium, dibasic calcium phosphate, hydroxypropyl cellulose, hypromellose, polyethylene glycol, magnesium stearate, microcrystalline cellulose, and titanium dioxide.



What does Cyclobenzaprine Hydrochloride look like?



What are the available doses of Cyclobenzaprine Hydrochloride?

Sorry No records found.

What should I talk to my health care provider before I take Cyclobenzaprine Hydrochloride?

Sorry No records found

How should I use Cyclobenzaprine Hydrochloride?

Cyclobenzaprine HCl is indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions.

Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living.

Cyclobenzaprine HCl should be used only for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted.

Cyclobenzaprine HCl has not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy.

For most patients, the recommended dose of cyclobenzaprine HCl is 5 mg three times a day. Based on individual patient response, the dose may be increased to either 7.5 mg or 10 mg three times a day. Use of cyclobenzaprine HCl for periods longer than two or three weeks is not recommended. (See )

Less frequent dosing should be considered for hepatically impaired or elderly patients (see, and).


What interacts with Cyclobenzaprine Hydrochloride?

Hypersensitivity to any component of this product.


Concomitant use of monoamine oxidase (MAO) inhibitors or within 14 days after their discontinuation. Hyperpyretic crisis seizures, and deaths have occurred in patients receiving cyclobenzaprine (or structurally similar tricyclic antidepressants) concomitantly with MAO inhibitor drugs.


Acute recovery phase of myocardial infarction, and patients with arrhythmias, heart block or conduction disturbances, or congestive heart failure.


Hyperthyroidism.



What are the warnings of Cyclobenzaprine Hydrochloride?

Rarely, ACE inhibitors have been associated with a syndrome that starts with cholestatic jaundice and progresses to fulminant hepatic necrosis and (sometimes) death. The mechanism of this syndrome is not understood. Patients receiving ACE inhibitors who develop jaundice or marked elevations of hepatic enzymes should discontinue the ACE inhibitor and receive appropriate medical follow-up.

Cyclobenzaprine is closely related to the tricyclic antidepressants, e.g., amitriptyline and imipramine. In short term studies for indications other than muscle spasm associated with acute musculoskeletal conditions, and usually at doses somewhat greater than those recommended for skeletal muscle spasm, some of the more serious central nervous system reactions noted with the tricyclic antidepressants have occurred (see, below, and).

Tricyclic antidepressants have been reported to produce arrhythmias, sinus tachycardia, prolongation of the conduction time leading to myocardial infarction and stroke.

Cyclobenzaprine HCl may enhance the effects of alcohol, barbiturates, and other CNS depressants.


What are the precautions of Cyclobenzaprine Hydrochloride?

General

Because of its atropine-like action, cyclobenzaprine HCl should be used with caution in patients with a history of urinary retention, angle-closure glaucoma, increased intraocular pressure, and in patients taking anticholinergic medication.

Impaired Hepatic Function

The plasma concentration of cyclobenzaprine is increased in patients with hepatic impairment (see ).

These patients are generally more susceptible to drugs with potentially sedating effects, including cyclobenzaprine. Cyclobenzaprine HCl should be used with caution in subjects with mild hepatic impairment starting with a 5 mg dose and titrating slowly upward. Due to the lack of data in subjects with more severe hepatic insufficiency, the use of cyclobenzaprine HCl in subjects with moderate to severe impairment is not recommended.

Information for Patients

Cyclobenzaprine HCl, especially when used with alcohol or other CNS depressants, may impair mental and/or physical abilities required for performance of hazardous tasks, such as operating machinery or driving a motor vehicle. In the elderly, the frequency and severity of adverse events associated with the use of cyclobenzaprine, with or without concomitant medications, is increased. In elderly patients, cyclobenzaprine HCl should be initiated with a 5 mg dose and titrated slowly upward.

Drug Interactions

Cyclobenzaprine HCl may have life-threatening interactions with MAO inhibitors. (See )

Cyclobenzaprine HCl may enhance the effects of alcohol, barbiturates, and other CNS depressants. Tricyclic antidepressants may block the antihypertensive action of guanethidine and similarly acting compounds.

Tricyclic antidepressants may enhance the seizure risk in patients taking tramadol.

________________________

Array

Array

Carcinogenesis, Mutagenesis, Impairment of Fertility

In rats treated with cyclobenzaprine HCl for up to 67 weeks at doses of approximately 5 to 40 times the maximum recommended human dose, pale, sometimes enlarged, livers were noted and there was a dose-related hepatocyte vacuolation with lipidosis. In the higher dose groups this microscopic change was seen after 26 weeks and even earlier in rats which died prior to 26 weeks; at lower doses, the change was not seen until after 26 weeks.

Cyclobenzaprine did not affect the onset, incidence or distribution of neoplasia in an 81-week study in the mouse or in a 105-week study in the rat.

At oral doses of up to 10 times the human dose, cyclobenzaprine did not adversely affect the reproductive performance or fertility of male or female rats. Cyclobenzaprine did not demonstrate mutagenic activity in the male mouse at dose levels of up to 20 times the human dose.

Pregnancy

Pregnancy Category B

Reproduction studies have been performed in rats, mice and rabbits at doses up to 20 times the human dose, and have revealed no evidence of impaired fertility or harm to the fetus due to cyclobenzaprine HCl. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

Nursing Mothers

It is not known whether this drug is excreted in human milk. Because cyclobenzaprine is closely related to the tricyclic antidepressants, some of which are known to be excreted in human milk, caution should be exercised when cyclobenzaprine HCl is administered to a nursing woman.

Pediatric Use

Safety and effectiveness of cyclobenzaprine HCl in pediatric patients below 15 years of age have not been established.

Use in the Elderly

The plasma concentration of cyclobenzaprine is increased in the elderly (see ). The elderly may also be more at risk for CNS adverse events such as hallucinations and confusion, cardiac events resulting in falls or other sequelae, drug-drug and drug-disease interactions. For these reasons, in the elderly, cyclobenzaprine should be used only if clearly needed. In such patients cyclobenzaprine HCl should be initiated with a 5 mg dose and titrated slowly upward.


What are the side effects of Cyclobenzaprine Hydrochloride?

Incidence of most common adverse reactions in the 2 double-blind, placebo-controlled 5 mg studies (incidence of > 3% on cyclobenzaprine HCl 5 mg):

Adverse reactions which were reported in 1% to 3% of the patients were: abdominal pain, acid regurgitation, constipation, diarrhea, dizziness, nausea, irritability, mental acuity decreased, nervousness, upper respiratory infection, and pharyngitis.

The following list of adverse reactions is based on the experience in 473 patients treated with cyclobenzaprine HCl 10 mg in additional controlled clinical studies, 7607 patients in the post-marketing surveillance program, and reports received since the drug was marketed. The overall incidence of adverse reactions among patients in the surveillance program was less than the incidence in the controlled clinical studies.

The adverse reactions reported most frequently with cyclobenzaprine HCl were drowsiness, dry mouth and dizziness. The incidence of these common adverse reactions was lower in the surveillance program than in the controlled clinical studies:

Among the less frequent adverse reactions, there was no appreciable difference in incidence in controlled clinical studies or in the surveillance program. Adverse reactions which were reported in 1% to 3% of the patients were: fatigue/tiredness, asthenia, nausea, constipation, dyspepsia, unpleasant taste, blurred vision, headache, nervousness, and confusion.

The following adverse reactions have been reported in post-marketing experience or with an incidence of less than 1% of patients in clinical trials with the 10 mg tablet:

Body as a Whole:

Cardiovascular:

Digestive:

Hypersensitivity:

Musculoskeletal:

Nervous System and Psychiatric:

Skin:

Special Senses:

Urogenital:

________________________



Causal Relationship Unknown

Other reactions, reported rarely for cyclobenzaprine HCl under circumstances where a causal relationship could not be established or reported for other tricyclic drugs, are listed to serve as alerting information to physicians:

Body as a Whole:

Cardiovascular:

Digestive:

Endocrine:

Hematic and Lymphatic:

Metabolic, Nutritional and Immune:

Musculoskeletal:

Nervous System and Psychiatric:

Respiratory:

Skin:

Urogenital:

Cyclobenzaprine HCl TabletsCyclobenzaprine HCl TabletsPlacebo
5 mg10 mg
N=464N=249N=469
Drowsiness29%38%10%
Dry Mouth21%32%7%
Fatigue6%6%3%
Headache5%5%8%
Clinical Studies withSurveillance Program with
Cyclobenzaprine HCl Tablets 10 mgCyclobenzaprine HCl Tablets 10 mg
Drowsiness39%16%
Dry mouth27%7%
Dizziness11%3%



What should I look out for while using Cyclobenzaprine Hydrochloride?

Hypersensitivity to any component of this product.

Concomitant use of monoamine oxidase (MAO) inhibitors or within 14 days after their discontinuation. Hyperpyretic crisis seizures, and deaths have occurred in patients receiving cyclobenzaprine (or structurally similar tricyclic antidepressants) concomitantly with MAO inhibitor drugs.

Acute recovery phase of myocardial infarction, and patients with arrhythmias, heart block or conduction disturbances, or congestive heart failure.

Hyperthyroidism.

Cyclobenzaprine is closely related to the tricyclic antidepressants, e.g., amitriptyline and imipramine. In short term studies for indications other than muscle spasm associated with acute musculoskeletal conditions, and usually at doses somewhat greater than those recommended for skeletal muscle spasm, some of the more serious central nervous system reactions noted with the tricyclic antidepressants have occurred (see, below, and).

Tricyclic antidepressants have been reported to produce arrhythmias, sinus tachycardia, prolongation of the conduction time leading to myocardial infarction and stroke.

Cyclobenzaprine HCl may enhance the effects of alcohol, barbiturates, and other CNS depressants.



®



®


What might happen if I take too much Cyclobenzaprine Hydrochloride?

Although rare, deaths may occur from overdosage with cyclobenzaprine HCl. Multiple drug ingestion (including alcohol) is common in deliberate cyclobenzaprine overdose. Signs and symptoms of toxicity may develop rapidly after cyclobenzaprine overdose; therefore, hospital monitoring is required as soon as possible. The acute oral LD of cyclobenzaprine HCl is approximately 338 and 425 mg/kg in mice and rats, respectively.

Manifestations

The most common effects associated with cyclobenzaprine overdose are drowsiness and tachycardia. Less frequent manifestations include tremor, agitation, coma, ataxia, hypertension, slurred speech, confusion, dizziness, nausea, vomiting, and hallucinations. Rare but potentially critical manifestations of overdose are cardiac arrest, chest pain, cardiac dysrhythmias, severe hypotension, seizures, and neuroleptic malignant syndrome. Changes in the electrocardiogram, particularly in QRS axis or width, are clinically significant indicators of cyclobenzaprine toxicity.

Other potential effects of overdosage include any of the symptoms listed under.

Management

General

As management of overdose is complex and changing, it is recommended that the physician contact a poison control center for current information on treatment.

In order to protect against the rare but potentially critical manifestations described above, obtain an ECG and immediately initiate cardiac monitoring. Protect the patient’s airway, establish an intravenous line and initiate gastric decontamination. Observation with cardiac monitoring and observation for signs of CNS or respiratory depression, hypotension, cardiac dysrhythmias and/or conduction blocks, and seizures is necessary. If signs of toxicity occur at any time during this period, extended monitoring is required. Monitoring of plasma drug levels should not guide management of the patient. Dialysis is probably of no value because of low plasma concentrations of the drug.

Gastrointestinal Decontamination

All patients suspected of an overdose with cyclobenzaprine HCl should receive gastrointestinal decontamination. This should include large volume gastric lavage followed by activated charcoal. If consciousness is impaired, the airway should be secured prior to lavage and emesis is contraindicated.

Cardiovascular

A maximal limb-lead QRS duration of ≥0.10 seconds may be the best indication of the severity of the overdose. Serum alkalinization, to a pH of 7.45 to 7.55, using intravenous sodium bicarbonate and hyperventilation (as needed), should be instituted for patients with dysrhythmias and/or QRS widening. A pH > 7.60 or a pCO
CNS

In patients with CNS depression, early intubation is advised because of the potential for abrupt deterioration. Seizures should be controlled with benzodiazepines or, if these are ineffective, other anticonvulsants (e.g. phenobarbital, phenytoin). Physostigmine is not recommended except to treat life-threatening symptoms that have been unresponsive to other therapies, and then only in close consultation with a poison control center.

Psychiatric Follow-Up

Since overdosage is often deliberate, patients may attempt suicide by other means during the recovery phase. Psychiatric referral may be appropriate.

Pediatric Management

The principles of management of child and adult overdosages are similar. It is strongly recommended that the physician contact the local poison control center for specific pediatric treatment.


How should I store and handle Cyclobenzaprine Hydrochloride?

Cyclobenzaprine Hydrochloride Tablets USP, 5 mg are round, white, film-coated tablets imprinted and .Cyclobenzaprine Hydrochloride Tablets USP, 7.5 mg are round, white, film-coated tablets imprinted and .Cyclobenzaprine Hydrochloride Tablets USP, 10 mg are round, white, film-coated tablets imprinted and .They are supplied by as follows:Dispense in a well-closed container with child-resistant closure.StoreWatson Laboratories, Inc.This Product was Repackaged By Sandhills Packaging For:Keltman Pharmaceuticals Inc.Cyclobenzaprine Hydrochloride Tablets USP, 5 mg are round, white, film-coated tablets imprinted and .Cyclobenzaprine Hydrochloride Tablets USP, 7.5 mg are round, white, film-coated tablets imprinted and .Cyclobenzaprine Hydrochloride Tablets USP, 10 mg are round, white, film-coated tablets imprinted and .They are supplied by as follows:Dispense in a well-closed container with child-resistant closure.StoreWatson Laboratories, Inc.This Product was Repackaged By Sandhills Packaging For:Keltman Pharmaceuticals Inc.Cyclobenzaprine Hydrochloride Tablets USP, 5 mg are round, white, film-coated tablets imprinted and .Cyclobenzaprine Hydrochloride Tablets USP, 7.5 mg are round, white, film-coated tablets imprinted and .Cyclobenzaprine Hydrochloride Tablets USP, 10 mg are round, white, film-coated tablets imprinted and .They are supplied by as follows:Dispense in a well-closed container with child-resistant closure.StoreWatson Laboratories, Inc.This Product was Repackaged By Sandhills Packaging For:Keltman Pharmaceuticals Inc.Cyclobenzaprine Hydrochloride Tablets USP, 5 mg are round, white, film-coated tablets imprinted and .Cyclobenzaprine Hydrochloride Tablets USP, 7.5 mg are round, white, film-coated tablets imprinted and .Cyclobenzaprine Hydrochloride Tablets USP, 10 mg are round, white, film-coated tablets imprinted and .They are supplied by as follows:Dispense in a well-closed container with child-resistant closure.StoreWatson Laboratories, Inc.This Product was Repackaged By Sandhills Packaging For:Keltman Pharmaceuticals Inc.Cyclobenzaprine Hydrochloride Tablets USP, 5 mg are round, white, film-coated tablets imprinted and .Cyclobenzaprine Hydrochloride Tablets USP, 7.5 mg are round, white, film-coated tablets imprinted and .Cyclobenzaprine Hydrochloride Tablets USP, 10 mg are round, white, film-coated tablets imprinted and .They are supplied by as follows:Dispense in a well-closed container with child-resistant closure.StoreWatson Laboratories, Inc.This Product was Repackaged By Sandhills Packaging For:Keltman Pharmaceuticals Inc.Cyclobenzaprine Hydrochloride Tablets USP, 5 mg are round, white, film-coated tablets imprinted and .Cyclobenzaprine Hydrochloride Tablets USP, 7.5 mg are round, white, film-coated tablets imprinted and .Cyclobenzaprine Hydrochloride Tablets USP, 10 mg are round, white, film-coated tablets imprinted and .They are supplied by as follows:Dispense in a well-closed container with child-resistant closure.StoreWatson Laboratories, Inc.This Product was Repackaged By Sandhills Packaging For:Keltman Pharmaceuticals Inc.Cyclobenzaprine Hydrochloride Tablets USP, 5 mg are round, white, film-coated tablets imprinted and .Cyclobenzaprine Hydrochloride Tablets USP, 7.5 mg are round, white, film-coated tablets imprinted and .Cyclobenzaprine Hydrochloride Tablets USP, 10 mg are round, white, film-coated tablets imprinted and .They are supplied by as follows:Dispense in a well-closed container with child-resistant closure.StoreWatson Laboratories, Inc.This Product was Repackaged By Sandhills Packaging For:Keltman Pharmaceuticals Inc.Cyclobenzaprine Hydrochloride Tablets USP, 5 mg are round, white, film-coated tablets imprinted and .Cyclobenzaprine Hydrochloride Tablets USP, 7.5 mg are round, white, film-coated tablets imprinted and .Cyclobenzaprine Hydrochloride Tablets USP, 10 mg are round, white, film-coated tablets imprinted and .They are supplied by as follows:Dispense in a well-closed container with child-resistant closure.StoreWatson Laboratories, Inc.This Product was Repackaged By Sandhills Packaging For:Keltman Pharmaceuticals Inc.Cyclobenzaprine Hydrochloride Tablets USP, 5 mg are round, white, film-coated tablets imprinted and .Cyclobenzaprine Hydrochloride Tablets USP, 7.5 mg are round, white, film-coated tablets imprinted and .Cyclobenzaprine Hydrochloride Tablets USP, 10 mg are round, white, film-coated tablets imprinted and .They are supplied by as follows:Dispense in a well-closed container with child-resistant closure.StoreWatson Laboratories, Inc.This Product was Repackaged By Sandhills Packaging For:Keltman Pharmaceuticals Inc.


&times

Clinical Information

Chemical Structure

No Image found
Clinical Pharmacology

Estimates of mean oral bioavailability of cyclobenzaprine range from 33% to 55%. Cyclobenzaprine exhibits linear pharmacokinetics over the dose range 2.5 mg to 10 mg, and is subject to enterohepatic circulation. It is highly bound to plasma proteins. Drug accumulates when dosed three times a day, reaching steady-state within 3-4 days at plasma concentrations about four-fold higher than after a single dose. At steady state in healthy subjects receiving 10 mg t.i.d. (n=18), peak plasma concentration was 25.9 ng/mL (range, 12.8-46.1 ng/mL), and area under the concentration-time (AUC) curve over an 8-hour dosing interval was 177 ng.hr/mL (range, 80-319 ng.hr/mL).

Cyclobenzaprine is extensively metabolized, and is excreted primarily as glucuronides via the kidney. Cytochromes P-450 3A4, 1A2, and, to a lesser extent, 2D6, mediate N-demethylation, one of the oxidative pathways for cyclobenzaprine. Cyclobenzaprine is eliminated quite slowly, with an effective half-life of 18 hours (range 8-37 hours; n=18); plasma clearance is 0.7 L/min.

The plasma concentration of cyclobenzaprine is generally higher in the elderly and in patients with hepatic impairment. (See and )

Non-Clinical Toxicology
Hypersensitivity to any component of this product.

Concomitant use of monoamine oxidase (MAO) inhibitors or within 14 days after their discontinuation. Hyperpyretic crisis seizures, and deaths have occurred in patients receiving cyclobenzaprine (or structurally similar tricyclic antidepressants) concomitantly with MAO inhibitor drugs.

Acute recovery phase of myocardial infarction, and patients with arrhythmias, heart block or conduction disturbances, or congestive heart failure.

Hyperthyroidism.

Cyclobenzaprine is closely related to the tricyclic antidepressants, e.g., amitriptyline and imipramine. In short term studies for indications other than muscle spasm associated with acute musculoskeletal conditions, and usually at doses somewhat greater than those recommended for skeletal muscle spasm, some of the more serious central nervous system reactions noted with the tricyclic antidepressants have occurred (see, below, and).

Tricyclic antidepressants have been reported to produce arrhythmias, sinus tachycardia, prolongation of the conduction time leading to myocardial infarction and stroke.

Cyclobenzaprine HCl may enhance the effects of alcohol, barbiturates, and other CNS depressants.

Cyclobenzaprine HCl may have life-threatening interactions with MAO inhibitors. (See )

Cyclobenzaprine HCl may enhance the effects of alcohol, barbiturates, and other CNS depressants. Tricyclic antidepressants may block the antihypertensive action of guanethidine and similarly acting compounds.

Tricyclic antidepressants may enhance the seizure risk in patients taking tramadol.

________________________

Array

Array

Because of its atropine-like action, cyclobenzaprine HCl should be used with caution in patients with a history of urinary retention, angle-closure glaucoma, increased intraocular pressure, and in patients taking anticholinergic medication.

Incidence of most common adverse reactions in the 2 double-blind, placebo-controlled 5 mg studies (incidence of > 3% on cyclobenzaprine HCl 5 mg):

Adverse reactions which were reported in 1% to 3% of the patients were: abdominal pain, acid regurgitation, constipation, diarrhea, dizziness, nausea, irritability, mental acuity decreased, nervousness, upper respiratory infection, and pharyngitis.

The following list of adverse reactions is based on the experience in 473 patients treated with cyclobenzaprine HCl 10 mg in additional controlled clinical studies, 7607 patients in the post-marketing surveillance program, and reports received since the drug was marketed. The overall incidence of adverse reactions among patients in the surveillance program was less than the incidence in the controlled clinical studies.

The adverse reactions reported most frequently with cyclobenzaprine HCl were drowsiness, dry mouth and dizziness. The incidence of these common adverse reactions was lower in the surveillance program than in the controlled clinical studies:

Among the less frequent adverse reactions, there was no appreciable difference in incidence in controlled clinical studies or in the surveillance program. Adverse reactions which were reported in 1% to 3% of the patients were: fatigue/tiredness, asthenia, nausea, constipation, dyspepsia, unpleasant taste, blurred vision, headache, nervousness, and confusion.

The following adverse reactions have been reported in post-marketing experience or with an incidence of less than 1% of patients in clinical trials with the 10 mg tablet:

Body as a Whole:

Cardiovascular:

Digestive:

Hypersensitivity:

Musculoskeletal:

Nervous System and Psychiatric:

Skin:

Special Senses:

Urogenital:

________________________



Causal Relationship Unknown

Other reactions, reported rarely for cyclobenzaprine HCl under circumstances where a causal relationship could not be established or reported for other tricyclic drugs, are listed to serve as alerting information to physicians:

Body as a Whole:

Cardiovascular:

Digestive:

Endocrine:

Hematic and Lymphatic:

Metabolic, Nutritional and Immune:

Musculoskeletal:

Nervous System and Psychiatric:

Respiratory:

Skin:

Urogenital:

&times

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

&times

Review

Rate this treatment and share your opinion


Helpful tips to write a good review:

  1. Only share your first hand experience as a consumer or a care giver.
  2. Describe your experience in the Comments area including the benefits, side effects and how it has worked for you. Do not provide personal information like email addresses or telephone numbers.
  3. Fill in the optional information to help other users benefit from your review.

Reason for Taking This Treatment

(required)

Click the stars to rate this treatment

This medication has worked for me.




This medication has been easy for me to use.




Overall, I have been satisfied with my experience.




Write a brief description of your experience with this treatment:

2000 characters remaining

Optional Information

Help others benefit from your review by filling in the information below.
I am a:
Gender:
&times

Professional

Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72
&times

Tips

Tips

&times

Interactions

Interactions

A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).